Asia Cervical Cancer Screening Market, Size, Forecast 2024-2032, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis
Buy NowAsia Cervical Cancer Screening Market Size
Asia Cervical Cancer Screening Market will reach to US$ 5.46 billion by 2032 up from US$ 3.76 billion in 2023. This expected growth is going to be a CAGR 4.23% between 2024 and 2032. Women health and preventive medicine has been of most concern resulting into development and supporting cervical cancer screening campaigns, vaccination and treatment services with aim of eradicating cervical cancer.
Asia Cervical Cancer Screening Market Outlooks
Cervical cancer screening is a health promotion check aiming at identifying abnormal cells or cervical cancer at early stages in women. These are such techniques as the Pap smear test and human papillomavirus (HPV) testing. These tests involve testing of samples of cervix cells to determine if there are any precancerous conditions that if not treated can cause cancer. Screening ought to be routine to enhance detection of cervical cancer in its early stages to ensure that it is controlled right from the time it is discovered hence lowered mortality rates associated with cervical cancer.
Screening for cervical cancer has some differences depending on the available health facilities and policies within the respective countries. In developed countries, women are invited for screening in organized screening programmes; with most of them screened every 3- 5 years. But absolute coverage is still relatively low worldwide because of financial issues, poor infrastructure, and population traditions in LMICs. However, there is continued endeavour in developing better feasible means of screening in a resource constrained environment as in use of visual inspection with acetic acid (VIA). World health bodies have embarked on sensitization campaigns and enhancement of cervical cancer screening in order to decrease the prevalence of the ailment in the world.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 3.76 Billion |
|
Market Forecast in 2032 |
US$ 5.46 Billion |
|
Market Growth Rate (2024-2032) |
4.23% |
Driving Forces of the Asia Cervical Cancer Screening Market
Increasing awareness and government initiatives:
The governments of all Asian countries understand the significance of cervical cancer prevention and introduce cervical cancer screening programs at the national level. Many countries including South Korea, Singapore, and Thailand also introduced comprehensive campaigns to enhance the awareness about breast cancer and screening services. Some of the interventions comprise mass awareness campaigns, low cost or free cervical cancer checks, and cervical cancer screening as a part of a general package in the primary care. Also, non-governmental organizations and international health care organizations work with the local authorities to ensure that screening reaches the rural and underprivileged populations. These favorable governmental policies in addition to the growing awareness among the female populace of the province regarding early detection of cervical cancer fuel the growth of cervical Cancer Screening Market in Asia. The government has proposed the use of vaccines for girls in the age of 9-14 years for vaccination against the human papillomavirus (HPV) for cervical cancer. This initiative was announced by Union Finance Minister in the Interim Budget 2024-25.
Technological advancements in screening methods:
Asia cervical cancer screening market is in the growing phase due to development in the screening techniques. This primary screening is being done by more advanced forms of cytopathological examination such as liquid based techniques, HPV DNA detection and computer aided screening. Hu et al forthcoming reviewed that by using these technologies, there is enhanced ability in the detection of precancerous lesions with higher sensitivity and specificity. Similarly, portable screening devices, and point-of-care tests reduce the challenges of cervical cancer screening in the rural areas. The use of artificial intelligence and machine learning to analyse screening results improve the diagnostic tools accuracy and efficiency as well. These technologies are gradually becoming available and more affordable and as such the cervical cancer screening gains more popularity in the different forms of healthcare facilities in Asia.
Growing healthcare expenditure and infrastructure development:
New healthcare consumers are appearing as Asian middle class increases and disposable rate grows resulting in higher healthcare expenditures. This has the flair of enabling more profound investment on healthcare actions such as cancer screening stations. Several Asian countries focus on establishing multispecialty cancer care facilities and enhancement of modernisation in existing healthcare centers having cancer diagnosis amenities. There is also provision of the cervical cancer screening services that is provided by the private healthcare sector. In addition, enrolment in health insurance plans where preventive care such as cancer screening examinations is included as part of the policy benefit is slowly gaining ground in several Asian countries. Enhanced cares health policies as well as care funding aids the large population in getting cervical cancer screening hence boosting market demand. China’s total health expenditure in 2022 was over 8.5 trillion yuan, including government, collective, and private out-of-pocket spending.
Japan Cervical Cancer Screening Market
Japan cervical cancer screening market is well developed and the focus is made on the preventive measures. Japan has developed a cervical cancer screening program for the entire nation where women of 20 years and above are advised to undergo pap test regularly. The country has over these years passed through changes from conventional to liquid-based cytology and has adopted HPV testing in screening. However, participation rate of screening has traditionally been lowering in Japan than in other comparable countries and continuous efforts have been made for raising the level of awareness towards screening.
Current development in the market includes automation of screening techniques through screening machines as well as molecular testing. Japanese companies also actively work on developing new sophisticated screening technologies so that the market is growing. However, great challenges such as the growth of an aging population and changing lifestyle keep influencing the occurrence in cervical cancer. Cervical cancer screening in Japan is efficient now, but authorities and health care providers are seeking for an increased accessibility of screening, especially in rural areas and the development of new approaches to improve the cervical cancer early detection and prevention.
Asia Cervical Cancer Screening Company Analysis
Abbott Laboratories, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health are the main actors in the Asia Cervical Cancer Screening industry.
Asia Cervical Cancer Screening Company News
Feb 2024: BD announced a partnership with Camtech Health to offer the first-ever at-home cervical cancer screening option for women in Singapore.
In June 2022, Roche has launched a new HPV self-sampling solution that allows patients to collect their own vaginal samples for HPV screening at a healthcare facility. The samples are analyzed using the Roche cobas® HPV test on a Roche molecular instrument.
May 2024, The Genomics Institute-BGI Genomics launched a cervical cancer screening program at Remera Health Center in cooperation with the Rwanda Biomedical Center.
June 2023, Crowell & Moring International, Roche, TogetHER for Health, CAPED, and Jhpiego are founding the Asia-Pacific Women's Cancer Coalition to address the rise in breast and cervical cancer cases in the Asia-Pacific region.
Type – Market has been covered from 3 viewpoints:
- Pap smear Market
- HPV DNA Market
- VIA (visual inspection with acetic acid) Market
Pap smear Market – 8 Country have been covered
- Japan
- Korea
- Singapore
- Malaysia
- India
- China
- Thailand
- Indonesia
HPV DNA Market – 7 Country have been covered
- Japan
- Korea
- Singapore
- Malaysia
- India
- China
- Indonesia
VIA (visual inspection with acetic acid) Market – 4 Country have been covered
- India
- China
- Thailand
- Indonesia
Companies have been covered from 4 viewpoints
- Overviews
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
Company Covered
- Abbott laboratories
- Hologic Corporation
- Becton
- Siemens AG
- Roche Diagnostics
- Quest Diagnostics
- Cardinal Health
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Billion |
| Segment Covered |
HPV DNA, VIA and Countries |
| Countries Covered |
|
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Porter’s Five Forces
5.1 Bargaining Power of Buyer
5.2 Bargaining Power of Supplier
5.3 Threat of New Entrants
5.4 Rivalry among Existing Competitors
5.5 Threat of Substitute Products
6. SWOT Analysis
6.1 Strengths
6.2 Weaknesses
6.3 Opportunities
6.4 Threats
7. Asia pacific Cervical Cancer Screening Analysis
7.1 Asia pacific Cervical Cancer Market
7.2 Asia pacific Cervical Cancer Population
8. Asia Cervical Cancer Test (Screening) Analysis
8.1 Asia Cervical Cancer Test Population
8.1.1 Pap smear Test Population
8.1.2 HPV DNA Test Population
8.1.3 VIA Test Population
8.2 Asia Cervical Cancer Test (Screening) Market
8.2.1 Pap Smear Test Market
8.2.2 HPV DNA Test Market
8.2.3 Visual Inspection with Acetic Acid (VIA) Test Market
9. By Countries Share Analysis
9.1 Asia Cervical Cancer Test Population Share
9.1.1 Pap Smear Population
9.1.2 HPV DNA Population
9.1.3 VIA Population
9.2 Asia Cervical Cancer Market Share
9.2.1 Pap Smear Market
9.2.2 HPV DNA Market
9.2.3 VIA Market
10. Japan – Cervical Cancer Test Analysis
10.1 Population - Cervical Cancer Test (Screening)
10.1.1 Pap smear Test Population
10.1.2 HPV DNA Test Population
10.2 Market – Cervical Cancer Test (Screening)
10.2.1 Pap Smear Test Market
10.2.2 HPV DNA Test Market
11. South Korea – Cervical Cancer Tests Analysis
11.1 Population – Cervical Cancer Test (Screening)
11.1.1 Pap Smear Test Population
11.1.2 HPV DNA Test Population
11.2 Market – Cervical Cancer Test (Screening)
11.2.1 Pap Smear Test Market
11.2.2 HPV DNA Test Market
12. Singapore – Cervical Cancer Tests Analysis
12.1 Population – Cervical Cancer Test (Screening)
12.1.1 Pap Smear Test Population
12.1.2 HPV DNA Test Population
12.2 Market – Cervical Cancer Test (Screening)
12.2.1 Pap Smear Test Market
12.2.2 HPV DNA Test Market
13. Malaysia – Cervical Cancer Test Analysis
13.1 Population – Cervical Cancer Test (Screening)
13.1.1 Pap Smear Test Population
13.1.2 HPV DNA Test Population
13.2 Market – Cervical Cancer Test (Screening)
13.3 Pap Smear Test Market
13.4 HPV DNA Test Market
14. India – Cervical Cancer Test Analysis
14.1 Population – Cervical Cancer Test (Screening)
14.1.1 Pap Smear Test Population
14.1.2 HPV DNA Test Population
14.1.3 VIA Test Population
14.2 Market – Cervical Cancer Test (Screening)
14.2.1 Pap Smear Test Market
14.2.2 HPV DNA Test Market
14.2.3 VIA Test Market
15. China – Cervical Cancer Test Analysis
15.1 Population – Cervical Cancer Test (Screening)
15.1.1 Pap Smear Test Population
15.1.2 HPV DNA Test Population
15.1.3 VIA Test Population
15.2 Market – Cervical Cancer Test (Screening)
15.2.1 Pap Smear Test Population
15.2.2 HPV DNA Test Population
15.2.3 VIA Test Market
16. Thailand – Cervical Cancer Test Analysis
16.1 Population – Cervical Cancer Test (Screening)
16.1.1 Pap Smear Test Population
16.1.2 VIA Test Population
16.2 Market – Cervical Cancer Test (Screening)
16.2.1 Pap Smear Test Market
16.2.2 VIA Test Market
17. Indonesia – Cervical Cancer Test Analysis
17.1 Population – Cervical Cancer Test (Screening)
17.1.1 Pap Smear Test Population
17.1.2 HPV DNA Test Population
17.1.3 VIA Test Population
17.1.4 Pap smear & VIA Test Population
17.2 Market – Cervical Cancer Test (Screening)
17.2.1 Pap smear Test Market
17.2.2 HPV DNA Test Market
17.2.3 VIA Test Market
17.2.4 Pap smear & VIA Test Market
18. Company Analysis
18.1 Abbott laboratories
18.1.1 Overviews
18.1.2 Recent Developments & Strategies
18.1.3 Product Portfolio & Product Launch in Last 1 Year
18.1.4 Revenue
18.2 Hologic Corporation
18.2.1 Overviews
18.2.2 Recent Developments & Strategies
18.2.3 Product Portfolio & Product Launch in Last 1 Year
18.2.4 Revenue
18.3 Becton
18.3.1 Overviews
18.3.2 Recent Developments & Strategies
18.3.3 Product Portfolio & Product Launch in Last 1 Year
18.3.4 Revenue
18.4 Siemens AG
18.4.1 Overviews
18.4.2 Recent Developments & Strategies
18.4.3 Product Portfolio & Product Launch in Last 1 Year
18.4.4 Revenue
18.5 Roche Diagnostics
18.5.1 Overviews
18.5.2 Recent Developments & Strategies
18.5.3 Product Portfolio & Product Launch in Last 1 Year
18.5.4 Revenue
18.6 Quest Diagnostics
18.6.1 Overviews
18.6.2 Recent Developments & Strategies
18.6.3 Product Portfolio & Product Launch in Last 1 Year
18.6.4 Revenue
18.7 Cardinal Health
18.7.1 Overviews
18.7.2 Recent Developments & Strategies
18.7.3 Product Portfolio & Product Launch in Last 1 Year
18.7.4 Revenue
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com